Tempus AI Stock Falls Despite Collaboration Announcement With Genialis

Tempus AI, Inc. (TEM) recently announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.The collaboration between Tempus and Genialis is likely to prove beneficial by combining the former’s expertise in clinical and molecular data with the latter’s AI-driven analytics. Together, they aim to develop advanced RNA-based biomarker algorithms, which can improve the ac ...